KR20240002018A - Composition for Skin Whitening Comprising Extract or Fraction of Cissus Quadrangularis as an Active Ingredient - Google Patents
Composition for Skin Whitening Comprising Extract or Fraction of Cissus Quadrangularis as an Active Ingredient Download PDFInfo
- Publication number
- KR20240002018A KR20240002018A KR1020220079107A KR20220079107A KR20240002018A KR 20240002018 A KR20240002018 A KR 20240002018A KR 1020220079107 A KR1020220079107 A KR 1020220079107A KR 20220079107 A KR20220079107 A KR 20220079107A KR 20240002018 A KR20240002018 A KR 20240002018A
- Authority
- KR
- South Korea
- Prior art keywords
- cissus
- ethyl acetate
- extract
- acetate fraction
- fraction
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 119
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000002087 whitening effect Effects 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title claims abstract description 22
- 244000045483 Cissus quadrangularis Species 0.000 title claims abstract description 9
- 235000000470 Vitis quadrangularis Nutrition 0.000 title claims abstract description 9
- 239000002038 ethyl acetate fraction Substances 0.000 claims abstract description 67
- 230000000694 effects Effects 0.000 claims abstract description 56
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 48
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 48
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- 208000031019 skin pigmentation disease Diseases 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 241001355260 Cissus Species 0.000 claims description 123
- 235000017003 Cissus Nutrition 0.000 claims description 123
- 235000017014 Cissus repens Nutrition 0.000 claims description 123
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 94
- 230000008099 melanin synthesis Effects 0.000 claims description 60
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims description 24
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 208000003351 Melanosis Diseases 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 206010014970 Ephelides Diseases 0.000 claims description 4
- 206010008570 Chloasma Diseases 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 16
- 230000003013 cytotoxicity Effects 0.000 abstract description 16
- 206010040829 Skin discolouration Diseases 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 230000003061 melanogenesis Effects 0.000 abstract 1
- 230000003101 melanogenic effect Effects 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 74
- 239000000469 ethanolic extract Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 33
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 33
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 33
- 230000005764 inhibitory process Effects 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 18
- 229960004705 kojic acid Drugs 0.000 description 18
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 18
- 230000003834 intracellular effect Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000013641 positive control Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000012223 aqueous fraction Substances 0.000 description 11
- 239000002034 butanolic fraction Substances 0.000 description 11
- 239000002036 chloroform fraction Substances 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 11
- 239000002044 hexane fraction Substances 0.000 description 11
- 230000036564 melanin content Effects 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 5
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 5
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 5
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 5
- 108010051081 dopachrome isomerase Proteins 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 2
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- -1 cyclic monophosphate Chemical class 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 시서스(Cissus quadrangularis) 추출물 또는 이의 분획물을 유효성분으로 포함하는 피부 미백용 조성물에 관한 것으로, 보다 상세하게는 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 화장료 조성물에 관한 것이다.The present invention relates to a composition for skin whitening containing Cissus quadrangularis extract or a fraction thereof as an active ingredient, and more specifically, to a cosmetic composition for skin whitening containing Cissus hydrothermal extract or an ethyl acetate fraction thereof as an active ingredient. It relates to composition.
사람의 피부색은 멜라닌, 카로틴 및 헤모글로빈의 양에 따라 결정되는데 이중 멜라닌이 가장 결정적인 요소이다. 멜라닌은 피부 내 기저층에 존재하는 멜라노사이트(melanocyte)에서 합성되며 주변 각질세포(Keratinocyte)로 전이되어 사람의 피부색을 나타낸다. 멜라닌은 자외선으로부터 신체를 보호하는 중요한 기능을 가지고 있지만, 과잉 생산되는 경우에는 기미, 주근깨 등을 형성할 뿐 아니라 피부노화를 촉진하고 피부암유발에도 중요한 역할을 하는 것으로 알려져 있다.A person's skin color is determined by the amount of melanin, carotene, and hemoglobin, of which melanin is the most decisive factor. Melanin is synthesized in melanocytes present in the basal layer of the skin and is transferred to surrounding keratinocytes, giving human skin color. Melanin has an important function of protecting the body from ultraviolet rays, but when overproduced, it is known to not only form spots and freckles, but also accelerate skin aging and play an important role in causing skin cancer.
멜라닌은 멜라노사이트 세포에서 티로신(Tyrosine)의 효소 및 비효소적 산화반응을 거쳐 생성되는데 멜라닌 합성에 관여하는 효소로는 티로시나아제(tyrosinase), 티로시나아제 관련 단백질 1(tyrosinase related protein 1, TRP-1)과 티로시나아제 관련 단백질 2(tyrosinase related protein 2, TRP-2)가 알려져 있다. 또한 주요한 세포 내 신호전달 경로는 cAMP/PKA(cyclic monophosphate/protein kinase A) 경로로서, cAMP는 PKA, CREB1(cAMP resposive element binding protein 1)을 경유하여 MITF(Microphthalmia-associated transcription factor)의 발현을 촉진한다. MITF는 멜라닌 합성 과정에서 중요한 전사 조절 인자로 티로시나아제, 티로시나아제 관련 단백질1과 티로시나아제 관련 단백질 2의 전사를 촉진하는 것으로 알려져 있다. 또한, α-MSH(alpha-melanocyte stimulating hormone)는 세포막 수용체인 MC1R(melanocortin-1-receptor)를 통해 cAMP(cyclic AMP), PKA(protein kinase A)를 증가시키고 활성화된 MITF에 의해 티로시나아제의 발현을 조절함으로써 멜라닌세포의 증식과 색소증가에 관여한다 (Curto, E. V. et. al., Biochem. Pharmacol., 57:663-672, 1999; Bentley, N. J. et. al., Mol. Cell. Biol., 14:7996-8006, 1994). Melanin is produced through enzymatic and non-enzymatic oxidation reactions of tyrosine in melanocyte cells. The enzymes involved in melanin synthesis are tyrosinase and tyrosinase related protein 1 (TRP). -1) and tyrosinase related protein 2 (TRP-2) are known. In addition, the main intracellular signaling pathway is the cAMP/PKA (cyclic monophosphate/protein kinase A) pathway, and cAMP promotes the expression of MITF (Microphthalmia-associated transcription factor) via PKA and CREB1 (cAMP resposive element binding protein 1). do. MITF is an important transcriptional regulator in the melanin synthesis process and is known to promote the transcription of tyrosinase, tyrosinase-related protein 1, and tyrosinase-related protein 2. In addition, α-MSH (alpha-melanocyte stimulating hormone) increases cAMP (cyclic AMP) and PKA (protein kinase A) through MC1R (melanocortin-1-receptor), a cell membrane receptor, and increases tyrosinase production by activated MITF. By regulating expression, it is involved in the proliferation and pigmentation of melanocytes (Curto, EV et. al. , Biochem. Pharmacol. , 57:663-672, 1999; Bentley, NJ et. al. , Mol. Cell. Biol. , 14:7996-8006, 1994).
이에, 멜라닌 합성 저해 기작을 이용한 피부 미백용 화장료 조성물에 대한 연구가 많이 이루어지고 있으며, 특히 식물 유래 소재 또는 생약 성분은 안정성 측면에서 우수하여, 이를 이용한 기능성 소재 개발이 활발히 이루어지고 있다.Accordingly, much research is being conducted on cosmetic compositions for skin whitening using melanin synthesis inhibition mechanisms. In particular, plant-derived materials or herbal medicine ingredients are excellent in terms of stability, and the development of functional materials using them is actively being conducted.
한편, 시서스(Cissus quadrangularis)는 갈매나무목 포도과 시수스속에 속하는 상록성 여러해살이풀로서, 인도담쟁이 넝쿨이라고도 불리는 허브의 한 종류를 의미한다. 시서스는 체내의 렙틴 호르몬 분비를 조절하여 천연 식욕억제제의 역할을 하는 것으로 알려져 있으며, 세로토닌의 호르몬 분비를 촉진하여 심리적 안정 효과를 나타내는 것으로 알려져 있다 (대한민국공개특허 제10-2021-0020438호). 또한, 시서스 메탄올 추출물의 멜리닌 생성 촉진 효과에 대해서도 보고된 바 있다 (Rao G.V. et. al., Research Journal of Chemical Sciences, 1(2): 25-29, 2011).Meanwhile, Cissus ( Cissus quadrangularis ) is an evergreen perennial plant belonging to the genus Cissus of the Buckthorn order, Grape family, and refers to a type of herb also called Indian ivy. Cissus is known to act as a natural appetite suppressant by regulating the secretion of leptin hormone in the body, and is known to have a psychological stabilizing effect by promoting the secretion of the hormone serotonin (Korean Patent Publication No. 10-2021-0020438). In addition, the effect of Cissus methanol extract on promoting melinin production has been reported (Rao GV et. al. , Research Journal of Chemical Sciences , 1(2): 25-29, 2011).
이에, 본 발명에서는 보다 효과가 우수하고 안정적으로 피부 내 멜라닌 생성을 감소시킬 수 있는 식물 유래 추출물을 선별하기 위해 예의 노력한 결과, 시서스 줄기 또는 잎 추출물이 멜라닌 세포에서 멜라닌 생성 및 티로시나아제(tyrosinase) 활성을 유의한 수준으로 억제하는 것을 확인하고, 본 발명을 완성하였다. Accordingly, in the present invention, we made diligent efforts to select plant-derived extracts that are more effective and can stably reduce melanin production in the skin. As a result, Cissus stem or leaf extracts inhibit melanin production and tyrosinase in melanocytes. ) It was confirmed that the activity was suppressed to a significant level, and the present invention was completed.
따라서, 본 발명의 목적은 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공하는 데 있다.Therefore, the purpose of the present invention is to provide a cosmetic composition for skin whitening containing Cissus thermal water extract or its ethyl acetate fraction as an active ingredient.
본 발명의 다른 목적은 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 건강기능식품 조성물, 피부 색소 침착 질환 예방 또는 치료용 약학 조성물, 및 피부 색소 침착 질환 예방 또는 개선용 의약외품 조성물을 제공하는 데 있다.Another object of the present invention is to provide a health functional food composition for skin whitening containing Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient, a pharmaceutical composition for preventing or treating skin pigmentation diseases, and a quasi-drug for preventing or improving skin pigmentation diseases. To provide a composition.
상기 목적을 달성하기 위해, To achieve the above purpose,
본 발명은 시서스(Cissus quadrangularis) 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for skin whitening containing Cissus quadrangularis thermal water extract or its ethyl acetate fraction as an active ingredient.
또한, 본 발명 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for skin whitening containing Cissus thermal water extract or its ethyl acetate fraction as an active ingredient.
또한, 본 발명은 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 색소 침착 질환 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating skin pigmentation disease, comprising Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient.
또한, 본 발명은 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 색소 침착 질환 예방 또는 개선용 의약외품 조성물을 제공한다.In addition, the present invention provides a quasi-drug composition for preventing or improving skin pigmentation disease, comprising Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient.
본 발명의 구체적인 일실시예에 있어서, 상기 시서스는 시서스 줄기 및 시서스 잎으로 구성된 군에서 선택된 어느 하나 이상일 수 있다. In a specific embodiment of the present invention, the Cissus may be any one or more selected from the group consisting of Cissus stem and Cissus leaf.
본 발명의 구체적인 다른 일실시예에 있어서, 상기 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물은 10 ~ 500 ㎍/㎖ 농도로 포함될 수 있다.In another specific embodiment of the present invention, the Cissus hydrothermal extract or its ethyl acetate fraction may be included at a concentration of 10 to 500 μg/ml.
본 발명의 구체적인 또 다른 일실시예에 있어서, 상기 시서스 열수 추출물은 시서스 100 중량부당 5 ~ 15 ℓ 물을 가한 후, 1 ~ 3 시간 동안 열을 가하여 추출할 수 있다. In another specific embodiment of the present invention, the Cissus hot water extract can be extracted by adding 5 to 15 liters of water per 100 parts by weight of Cissus and then applying heat for 1 to 3 hours.
본 발명의 구체적인 또 다른 일실시예에 있어서, 상기 에틸아세테이트 분획물은 In another specific embodiment of the present invention, the ethyl acetate fraction is
(a) 시서스 열수 추출물에서 헥산 용매를 첨가한 다음, 수상(aqueous phase)을 수득하는 단계;(a) adding hexane solvent to the Cissus hydrothermal extract and then obtaining an aqueous phase;
(b) 상기 수상에 클로로포름 용매를 첨가한 다음, 수상을 수득하는단계; 및 (b) adding chloroform solvent to the aqueous phase and then obtaining the aqueous phase; and
(c) 상기 수상에 에틸아세테이트 용매를 첨가한 다음, 에틸아세테이트 분획물을 수득하는 단계;를 포함하는 방법으로 제조될 수 있다.(c) adding ethyl acetate solvent to the aqueous phase and then obtaining an ethyl acetate fraction.
본 발명의 구체적인 또 다른 일실시예에 있어서, 상기 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물은 멜라닌(melanin) 생성 또는 티로시나아제(tyrosinase) 활성을 억제할 수 있다.In another specific embodiment of the present invention, the Cissus hydrothermal extract or its ethyl acetate fraction can inhibit melanin production or tyrosinase activity.
본 발명의 구체적인 또 다른 일실시예에 있어서, 상기 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물은 MITF(Microphthalmia-associated transcription factor) 생성 억제를 통해 멜라닌(melanin) 생성 또는 티로시나아제(tyrosinase) 활성을 억제할 수 있다.In another specific embodiment of the present invention, the Cissus hot water extract or its ethyl acetate fraction inhibits melanin production or tyrosinase activity through inhibition of MITF (Microphthalmia-associated transcription factor) production. can do.
본 발명에서는 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물이 세포 독성 없이 멜라닌 생성 세포에서 멜라닌 생성 및 티로시나아제(tyrosinase) 활성을 유의한 수준으로 억제하는 것을 확인하였으므로, 본 발명의 조성물은 피부 미백용 화장품, 피부미백용 건강기능식품, 피부 색소 침착 질환 예방 또는 치료용 의약품 및 피부 색소 침착 질환 예방 또는 개선용 의약외품 등으로 유용하게 활용될 수 있다.In the present invention, it was confirmed that Cissus thermal water extract or its ethyl acetate fraction significantly inhibits melanin production and tyrosinase activity in melanin-producing cells without cytotoxicity. Therefore, the composition of the present invention is a cosmetic for skin whitening. , it can be usefully used as health functional food for skin whitening, medicine for preventing or treating skin pigmentation disease, and quasi-drugs for preventing or improving skin pigmentation disease.
도 1은 건조 전 시서스 줄기 및 잎(왼쪽) 및 건조 후 시서스 줄기 및 잎(오른쪽)을 나타낸 도면이다.
도 2는 α-멜라닌세포 자극 호르몬(α-MSH)으로 자극된 흑색종 세포(B16F1 세포)에 다양한 시서스 추출물을 처리하였을 때, (A) 세포 외 멜라닌 함량, (B) 세포 내 멜라닌 함량, 및 (C) 세포 생존율을 확인한 데이터이다. 코직산(Kojic acid)는 양성대조군이며, WE는 열수 추출물, 50E는 50% 에탄올 추출물, 70E는 70% 에탄올 추출물, 100E는 100% 에탄올 추출물을 의미한다. 모든 도면에서 데이터는 평균 ± 표준편차 값(n=3)으로 나타내었다.
도 3은 α-MSH으로 자극된 B16F1 세포에 다양한 농도의 시서스 열수 추출물을 처리하였을 때, (A) 세포 외 멜라닌 함량, 및 (B) 세포 내 멜라닌 함량을 확인한 데이터이다.
도 4는 α-MSH으로 자극된 B16F1 세포에 다양한 농도의 시서스 열수 추출물을 처리하였을 때, 티로시나아제 활성을 확인한 데이터이다.
도 5는 α-MSH으로 자극된 B16F1 세포에 다양한 농도의 시서스 열수 추출물을 처리하였을 때, 멜라닌 생성 관련 단백질 발현 억제 효과를 확인한 데이터이다. (A)는 웨스턴블랏 데이터, (B)는 상대적 발현 정도를 확인한 데이터이다.
도 6은 시서스 열수 추출물의 분획물 제조방법에 대한 모식도이다.
도 7은 α-MSH으로 자극된 B16F1 세포에 시서스 열수 추출물의 다양한 분획물을 처리하였을 때, (A) 세포 외 멜라닌 함량, (B) 세포 내 멜라닌 함량, (C) 티로시나아제 활성, 및 (D) 세포 생존율을 확인한 데이터이다. 코직산(Kojic acid)는 양성대조군이며, WE는 열수 추출물, HF는 헥산 분획물, CF는 클로로포름 분획물, EF는 에틸아세테이트 분획물, BF는 n-부탄올 분획물, WF는 물 분획물을 의미한다.
도 8은 α-MSH으로 자극된 B16F1 세포에 다양한 농도의 시서스 열수 추출물의 에틸아세테이트 분획물을 처리하였을 때, (A) 세포 외 멜라닌 함량, (B) 세포 내 멜라닌 함량, (C) 티로시나아제 활성, 및 (D) 세포 생존율을 확인한 데이터이다.
도 9는 α-MSH으로 자극된 B16F1 세포에 다양한 농도의 시서스 열수 추출물의 에틸아세테이트 분획물을 처리하였을 때, 멜라닌 생성 관련 단백질 발현 억제 효과를 확인한 데이터이다. (A)는 웨스턴블랏 데이터, (B)는 상대적 발현 정도를 확인한 데이터이다.Figure 1 is a view showing Cissus stems and leaves before drying (left) and Cissus stems and leaves after drying (right).
Figure 2 shows (A) extracellular melanin content, (B) intracellular melanin content, when melanoma cells (B16F1 cells) stimulated with α-melanocyte stimulating hormone (α-MSH) were treated with various Cissus extracts. and (C) data confirming cell viability. Kojic acid is a positive control, WE means hot water extract, 50E means 50% ethanol extract, 70E means 70% ethanol extract, and 100E means 100% ethanol extract. In all figures, data are presented as mean ± standard deviation values (n = 3).
Figure 3 shows data confirming (A) extracellular melanin content and (B) intracellular melanin content when B16F1 cells stimulated with α-MSH were treated with various concentrations of Cissus hot water extract.
Figure 4 shows data confirming tyrosinase activity when B16F1 cells stimulated with α-MSH were treated with various concentrations of Cissus hot water extract.
Figure 5 shows data confirming the effect of suppressing the expression of proteins related to melanin production when B16F1 cells stimulated with α-MSH were treated with various concentrations of Cissus hot water extract. (A) is Western blot data, and (B) is data confirming the relative expression level.
Figure 6 is a schematic diagram of a method for producing fractions of Cissus hot water extract.
Figure 7 shows (A) extracellular melanin content, (B) intracellular melanin content, (C) tyrosinase activity, and (C) when α-MSH-stimulated B16F1 cells were treated with various fractions of Cissus hot water extract. D) Data confirming cell survival rate. Kojic acid is a positive control, WE means hot water extract, HF means hexane fraction, CF means chloroform fraction, EF means ethyl acetate fraction, BF means n-butanol fraction, and WF means water fraction.
Figure 8 shows (A) extracellular melanin content, (B) intracellular melanin content, and (C) tyrosinase when α-MSH-stimulated B16F1 cells were treated with various concentrations of ethyl acetate fraction of Cissus hot water extract. Data confirming activity, and (D) cell viability.
Figure 9 shows data confirming the effect of suppressing the expression of proteins related to melanin production when α-MSH-stimulated B16F1 cells were treated with various concentrations of ethyl acetate fraction of Cissus hot water extract. (A) is Western blot data, and (B) is data confirming the relative expression level.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 일관점에서, 시서스(Cissus quadrangularis) 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 화장료 조성물에 관한 것이다.The present invention generally relates to a cosmetic composition for skin whitening containing Cissus quadrangularis thermal water extract or its ethyl acetate fraction as an active ingredient.
본 발명에 있어서, 상기 시서스는 시서스 줄기 및 시서스 잎으로 구성된 군에서 선택된 어느 하나 이상일 수 있다. In the present invention, the Cissus may be any one or more selected from the group consisting of Cissus stem and Cissus leaf.
본 발명에 있어서, 상기 시서스 추출물은 10 ~ 500 ㎍/㎖ 농도로 포함될 수 있다. 상기 추출물의 농도가 10 ㎍/㎖ 미만인 경우에는 미백 효과가 미약할 수 있으며, 500 ㎍/㎖ 초과인 경우에는 함유량 증가에 따른 효과 증대 정도가 미미하며, 세포 독성 등의 문제가 나타날 수 있다.In the present invention, the Cissus extract may be included at a concentration of 10 to 500 μg/ml. If the concentration of the extract is less than 10 ㎍/㎖, the whitening effect may be weak, and if it is more than 500 ㎍/㎖, the degree of increase in effect as the content increases is negligible, and problems such as cytotoxicity may appear.
본 발명에 있어서, 상기 시서스 열수 추출물은 시서스 100 중량부당 5 ~ 15 ℓ 물을 가한 후, 1 ~ 3 시간 동안 열을 가하여 추출할 수 있다. In the present invention, the Cissus hot water extract can be extracted by adding 5 to 15 liters of water per 100 parts by weight of Cissus and then applying heat for 1 to 3 hours.
본 발명에 있어서, 상기 시서스 추출물은 멜라닌(melanin) 생성 또는 티로시나아제(tyrosinase) 활성을 억제할 수 있다.In the present invention, the Cissus extract can inhibit melanin production or tyrosinase activity.
본 발명에 있어서, 상기 시서스 추출물은 MITF(Microphthalmia-associated transcription factor) 생성 억제를 통해 멜라닌(melanin) 생성 또는 티로시나아제(tyrosinase) 활성을 억제할 수 있다.In the present invention, the Cissus extract can inhibit melanin production or tyrosinase activity by inhibiting MITF (Microphthalmia-associated transcription factor) production.
본 발명의 구체적인 일구현예에서, 줄기 및 잎을 포함하는 건조된 시서스를 이용하여 열수 추출물, 50% 에탄올 추출물, 70% 에탄올 추출물 및 100% 에탄올 추출물을 제조하였다. 제조된 시서스 추출물의 멜라난 생성 억제 효능을 확인한 결과, 시서스 열수 추출물, 50% 에탄올 추출물, 70% 에탄올 추출물 및 100% 에탄올 추출물 모두 세포 외 멜라닌 방출량 및 세포 내 멜라닌 생성량을 감소시키는 것으로 확인되었다. 하지만, 시서스 70% 에탄올 추출물 및 100% 에탄올 추출물은 세포 독성이 있는 것으로 나타났으며, 이들 추출물의 멜라닌 생성 효과는 세포 독성으로 인해 기인된 것으로 판단된다. In a specific embodiment of the present invention, hot water extract, 50% ethanol extract, 70% ethanol extract, and 100% ethanol extract were prepared using dried Cissus including stems and leaves. As a result of confirming the effectiveness of the prepared Cissus extract in suppressing melanan production, it was confirmed that Cissus thermal water extract, 50% ethanol extract, 70% ethanol extract, and 100% ethanol extract all reduced the amount of extracellular melanin released and the amount of intracellular melanin produced. . However, Cissus 70% ethanol extract and 100% ethanol extract were found to be cytotoxic, and the melanin production effect of these extracts is believed to be due to cytotoxicity.
반면, 시서스 열수 추출물 및 50% 에탄올 추출물은 200 ㎍/㎖ 농도에서도 세포 독성이 관찰되지 않았으므로, 이들 추출물, 특히 시서스 열수 추출물의 멜리닌 생성 억제 효능이 우수한 것을 확인하였다 (도 2).On the other hand, since cytotoxicity was not observed in the Cissus hot water extract and the 50% ethanol extract even at a concentration of 200 μg/ml, it was confirmed that these extracts, especially the Cissus hot water extract, were excellent in their efficacy in inhibiting melinin production (Figure 2).
본 발명의 구체적인 다른 일구현예에서, 시서스 열수 추출물의 멜라닌 생성 억제 효과를 확인한 결과, 멜라닌 생성 억제 및 티로시나아제 활성 저해 효과를 확인한 결과, 농도 의존적으로 α-MSH로 자극된 흑색종 세포의 세포 외 방출 멜라닌 및 세포 내 멜라닌 생성뿐만 아니라 티로시나아제 활성을 모두 억제하는 것을 확인하였다 (도 3 및 도 4).In another specific embodiment of the present invention, as a result of confirming the melanin production inhibition effect of the Cissus thermal water extract, the melanin production inhibition and tyrosinase activity inhibition effects were confirmed, and as a result, the melanoma cells stimulated with α-MSH were confirmed in a concentration-dependent manner. It was confirmed that both extracellularly released melanin and intracellular melanin production as well as tyrosinase activity were suppressed (Figures 3 and 4).
또한, 시서스 열수 추출물의 미백 관련 단백질이 발현 저해 효과를 확인한 결과, 시서스 열수 추출물에 의해 멜라닌 생성 과정의 주요 효소인 MITF의 발현이 억제되는 것을 확인하였다 (도 5). MITF(Microphthalmia-associated transcription factor)는 멜라닌합성 과정에 서 중요한 전사 조절 인자로 티로시나아제(tyrosinase), TRP-1 및 TRP-2의 전사를 촉진시키는 것으로 알려져있다.In addition, as a result of confirming the inhibitory effect on the expression of whitening-related proteins of the Cissus hot water extract, it was confirmed that the expression of MITF, a key enzyme in the melanin production process, was suppressed by the Cissus hot water extract (Figure 5). Microphthalmia-associated transcription factor (MITF) is an important transcriptional regulator in the melanin synthesis process and is known to promote the transcription of tyrosinase, TRP-1, and TRP-2.
본 발명에 있어서, 상기 시서스 열수 추출물의 에틸아세테이트 분획물은 In the present invention, the ethyl acetate fraction of the Cissus hot water extract is
(a) 시서스 열수 추출물에서 헥산 용매를 첨가한 다음, 수상(aqueous phase)을 수득하는 단계;(a) adding hexane solvent to the Cissus hydrothermal extract and then obtaining an aqueous phase;
(b) 상기 수상에 클로로포름 용매를 첨가한 다음, 수상을 수득하는단계; 및 (b) adding chloroform solvent to the aqueous phase and then obtaining the aqueous phase; and
(c) 상기 수상에 에틸아세테이트 용매를 첨가한 다음, 에틸아세테이트 분획물을 수득하는 단계;를 포함하는 방법으로 제조될 수 있다.(c) adding ethyl acetate solvent to the aqueous phase and then obtaining an ethyl acetate fraction.
본 발명의 구체적인 또 다른 일구현예에서, 미백 활성이 우수한 시서스 열수 추출물응ㄹ 이용하여 헥산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, 부탄올 분획물 및 물 분획물을 제조하였다 (도 6). 각 분획물의 세포 독성 및 멜라닌 생성 억제 효능을 확인한 결과, 분획물 모두 세포 독성은 관찰되지 않았으며, 에틸아세테이트 분획물이 멜라닌 생성 억제 효능 및 티로시나아제 활성 억제 효능이 가장 우수한 것으로 확인되었다 (도 7).In another specific embodiment of the present invention, hexane fraction, chloroform fraction, ethyl acetate fraction, butanol fraction, and water fraction were prepared using Cissus hydrothermal extract, which has excellent whitening activity (FIG. 6). As a result of confirming the cytotoxicity and melanin production inhibition efficacy of each fraction, no cytotoxicity was observed in any of the fractions, and the ethyl acetate fraction was confirmed to have the best efficacy in inhibiting melanin production and tyrosinase activity (Figure 7).
또한, 농도에 따른 시서스 열수 추출물의 에틸아세테이트 분획물의 멜라닌 생성 억제 및 티로시나아제 활성 저해 효과를 확인한 결과, 농도 의존적으로 α-MSH로 자극된 흑색종 세포의 세포 외 방출 멜라닌 및 세포 내 멜라닌 생성뿐만 아니라 티로시나아제 활성을 모두 억제하는 것을 확인하였다 (도 8A, 도 8B 및 도 8C). 나아가, 농도에 따른 시서스 열수 추출물의 에틸아세테이트 분획물의 세포 독성은 나타나지 않았으며, 오히려 세포 생존율이 증가되는 것을 확인하였다 (도 8D).In addition, as a result of confirming the effect of the ethyl acetate fraction of Cissus thermal water extract on concentration-dependent inhibition of melanin production and tyrosinase activity, extracellular melanin and intracellular melanin production in melanoma cells stimulated with α-MSH were found to be concentration-dependent. In addition, it was confirmed that all tyrosinase activities were inhibited (Figures 8A, 8B, and 8C). Furthermore, cytotoxicity of the ethyl acetate fraction of Cissus hot water extract did not appear depending on the concentration, and rather, cell viability was confirmed to increase (Figure 8D).
본 발명의 구체적인 또 다른 일구현예에서, 시서스 열수 추출물의 에틸아세테이트 분획물의 미백 관련 단백질이 발현 저해 효과를 확인한 결과, 에틸아세테이트 분획물에 의해 멜라닌 생성 과정의 주요 효소인 MITF의 발현이 억제되는 것을 확인하였다 (도 9).In another specific embodiment of the present invention, as a result of confirming the inhibitory effect on the expression of whitening-related proteins of the ethyl acetate fraction of Cissus thermal water extract, it was found that the expression of MITF, a key enzyme in the melanin production process, was suppressed by the ethyl acetate fraction. Confirmed (Figure 9).
즉, 본 발명의 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물은 멜라닌 생성 세포에서 유의한 수준으로 멜라닌 생성 억제 및 티로시나아제 활성 억제 효능을 나타낼뿐만 아니라, 멜라닌 생성 및 티로시나아제 활성과 관련된 단백질 발현을 억제하는 것을 확인하였다. 따라서, 본 발명의 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물은 피부 미백용 화장료 조성물, 피부 미백용 건강기능식품용 조성물, 피부 색소 침착 질환 예방 또는 치료용 약학 조성물 및 피부 색소 침착 질환 예방 또는 개선용 의약외품 조성물로 활용될 수 있다.In other words, the Cissus hot water extract or its ethyl acetate fraction of the present invention not only exhibits the efficacy of inhibiting melanin production and tyrosinase activity at a significant level in melanin-producing cells, but also inhibits the expression of proteins related to melanin production and tyrosinase activity. Suppression was confirmed. Therefore, the Cissus thermal water extract or its ethyl acetate fraction of the present invention can be used in cosmetic compositions for skin whitening, compositions for health functional foods for skin whitening, pharmaceutical compositions for preventing or treating skin pigmentation diseases, and quasi-drugs for preventing or improving skin pigmentation diseases. It can be used as a composition.
본 발명의 피부미백용 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 또는 스프레이의 제형일 수 있으며, 이에 한정되는 것은 아니다.The cosmetic composition for skin whitening of the present invention may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation or spray. It can be done, but is not limited to this.
본 발명은 다른 일관점에서, 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 미백용 건강기능식품 조성물에 관한 것이다.In another aspect, the present invention relates to a health functional food composition for skin whitening containing Cissus thermal water extract or its ethyl acetate fraction as an active ingredient.
상기 피부미백용 건강기능식품 조성물은 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가로 포함될 수 있다.The health functional food composition for skin whitening may additionally contain various flavoring agents or natural carbohydrates, like a typical food composition.
상기 건강기능식품의 제제 형태는 정제, 캅셀, 분말, 과립, 액상, 환 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제등 다른 통상의 첨가제를 첨가할 수 있다.The formulation form of the health functional food may be tablets, capsules, powders, granules, liquids, pills, etc. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Additionally, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tracacance or sodium oleate, sodium stearate, magnesium stearate, sodium Includes benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc. Acceptable pharmaceutical carriers for compositions formulated as liquid solutions include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these ingredients can be mixed and used, and other common additives such as antioxidants, buffers, and bacteriostatic agents can be added as needed.
본 발명은 또 다른 일관점에서, 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 색소 침착 질환 예방 또는 치료용 약학 조성물에 관한 것이다.In another consistent aspect, the present invention relates to a pharmaceutical composition for preventing or treating skin pigmentation disease, comprising Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient.
본 발명은 또 다른 일관점에서, 시서스 열수 추출물 또는 이의 에틸아세테이트 분획물을 유효성분으로 포함하는 피부 색소 침착 질환 예방 또는 개선용 의약외품 조성물에 관한 것이다. In another consistent aspect, the present invention relates to a quasi-drug composition for preventing or improving skin pigmentation disease, comprising Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient.
본 발명에서 상기 피부 색소 침착 질환은 기미(melasma), 주근깨(freckle), 흑색종(melanoma)으로 이루어진 군에서 선택된 적어도 어느 하나를 포함할 수 있으며, 이에 한정되는 것은 아니다.In the present invention, the skin pigmentation disease may include at least one selected from the group consisting of melasma, freckles, and melanoma, but is not limited thereto.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 다양한 형태로 제형화하여 사용될 수 있다. 예컨대, 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형으로 제형화할 수 있고, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 각각의 제형에 따라 약학적으로 허용가능한 담체, 부형제 및 희석제를 더 포함할 수 있다. 또한 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 외용제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention can be formulated and used in various forms according to conventional methods. For example, it can be formulated into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., and can be formulated and used in the form of external preparations, suppositories, and sterile injection solutions. Depending on each dosage form, it may further include pharmaceutically acceptable carriers, excipients, and diluents. In addition, it can be formulated and used in the form of external preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., and sterile injection solutions according to conventional methods.
상기 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유 등이 있다. 상기 약학 조성물을 제제화나 제형화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The carriers, excipients and diluents include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, These include microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil. When formulating or formulating the pharmaceutical composition, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
본 발명의 약학 조성물에 대한 치료상 유효 투여량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여시간, 투여 경로 및 조성물의분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자 등에 따라 조절될 수 있다. 본 발명의 약학 조성물은 개체에게 다양한 경로로 투여될 수 있다. 예를 들어, 정맥내, 복강내, 근육내, 동맥내, 구강, 심장내, 골수내, 경막내, 경피, 장관, 피하, 설하 또는 국소 투여할 수 있으나, 이에 제한되지 않는다. 본 발명의 약학 조성물은 1 ~ 10,000㎎/㎏/일의 양으로 투여할 수 있으며, 하루에 한번 투여할 수도 있고, 수 회에 나누어 투여할 수도 있다.It is obvious to those skilled in the art that the therapeutically effective dosage and frequency of administration of the pharmaceutical composition of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by a person skilled in the art, depending on the type of disease, the severity of the disease, the content of the active ingredient and other ingredients contained in the composition, the type of dosage form, the patient's age, weight, and general health condition. , gender and diet, administration time, administration route and secretion rate of the composition, treatment period, and various factors including concurrently used drugs. The pharmaceutical composition of the present invention can be administered to an individual through various routes. For example, it may be administered intravenously, intraperitoneally, intramuscularly, intraarterially, bucally, intracardiacally, intramedullary, intrathecally, transdermally, enterally, subcutaneously, sublingually, or topically, but is not limited thereto. The pharmaceutical composition of the present invention can be administered in an amount of 1 to 10,000 mg/kg/day, and may be administered once a day or divided into several times.
본 발명에서 사용되는 용어 "의약외품"은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미하는 것이다. 예를 들어 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람ㆍ동물의 질병 치료나 예방에 쓰이는 제품, 인체에 대한 작용이 경미하거나 직접 작용하지 않는 제품 등이 포함된다.The term "quasi-drug" used in the present invention refers to products that have a milder effect than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, alleviating, treating, or preventing diseases in humans or animals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs exclude products used for medicinal purposes and include products used to treat or prevent diseases in humans and animals, and products that have a mild or no direct effect on the human body.
본 발명의 의약외품 조성물은 피부 색소 침착 개선을 목적으로 사용되는 것으로, 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 마스크팩, 마스크시트, 젤 또는 피부 점착타입 화장료의 제형을 갖는 화장료 조성물일 수 있으며, 또한, 로션, 연고, 겔, 크림, 패취 또는 분무제와 같은 경피투여형 제형일 수 있다.The quasi-drug composition of the present invention is used for the purpose of improving skin pigmentation, and there is no particular limitation in its formulation, for example, softening lotion, nourishing lotion, massage cream, nutritional cream, pack, mask pack, mask sheet. , it may be a cosmetic composition having a gel or skin-adhesive cosmetic formulation, and may also be a transdermal formulation such as lotion, ointment, gel, cream, patch, or spray.
또한, 각 제형에 있어서 의약외품 조성물은 다른 성분들을 기타 의약외품의 제형 또는 사용목적 등에 따라 임의로 선정하여 배합할 수 있다. 유효 성분의 혼합양은 사용 목적(억제 또는 완화)에 따라 적합하게 결정될 수 있다. 예를 들어, 점증제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체 등을 포함할 수 있다.Additionally, in each dosage form, the quasi-drug composition may contain other ingredients selected arbitrarily depending on the formulation or purpose of use of the other quasi-drug composition. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (suppression or alleviation). For example, it may include conventional auxiliaries such as thickeners, stabilizers, solubilizers, vitamins, pigments and flavors, and carriers.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다.Hereinafter, the present invention will be described in more detail through examples.
이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.
시서스 추출물 제조Cissus Extract Manufacturing
본 발명에서 사용된 시서스는 국내산으로 녹우컴파운드에서 생시서스를 구입하여 건조 후 추출하여 시료로 사용하였다 (도 1).Cissus used in the present invention was domestically produced. Fresh Cissus was purchased from Nokwoo Compound, dried, extracted, and used as a sample (Figure 1).
건조된 시서스를 사용하여 물(열수 추출)과 50%(v/v) 에탄올, 70%(v/v) 에탄올, 100%(v/v) 에탄올로 추출하여 4종의 추출물을 제조하였다. Using dried Cissus, four types of extracts were prepared by extraction with water (hot water extraction), 50% (v/v) ethanol, 70% (v/v) ethanol, and 100% (v/v) ethanol.
열수 추출물은 시료 10g당 증류수 1ℓ를 넣고 전기약탕기 (대웅약탕기, 대웅바이오가전, 한국)를 이용하여 2시간 동안 끓인 후, 필터페이퍼 (advantec, No.41)를 이용하여 필터하였으며, 감압농축한 다음 동결 건조하였다. 50%(v/v) 에탄올 추출물, 70%(v/v) 에탄올 추출물 및 100%(v/v) 에탄올 추출물은 시료 시료 10g당 증류수 1ℓ를 넣은 후 1시간 동안 초음파 처리(sonicate) 한 다음 상온에서 하룻밤 동안(overnight) 반응시켜 1차 추출하였고, 다음날 1차 추출용매를 제거한 후 다시 용매 1ℓ를 추가하여 같은 방법으로 2차 추출하였다. 1차 추출물 및 2차 추출물을 모아 필터 후 감압농축한 다음 동결건조하여 각 추출물을 제조하였다. For the hot water extract, 1 liter of distilled water was added per 10 g of sample, boiled for 2 hours using an electric water boiler (Daewoong Medicine Water Boiler, Daewoong Bio Appliances, Korea), filtered using filter paper (Advantec, No. 41), and concentrated under reduced pressure. It was freeze-dried. For the 50% (v/v) ethanol extract, 70% (v/v) ethanol extract, and 100% (v/v) ethanol extract, add 1 liter of distilled water per 10 g of sample, sonicate for 1 hour, and then cool to room temperature. Primary extraction was performed by reacting overnight, and the next day, after removing the primary extraction solvent, 1 liter of solvent was added again and secondary extraction was performed in the same manner. The primary and secondary extracts were collected, filtered, concentrated under reduced pressure, and then freeze-dried to prepare each extract.
건조 시서스를 이용한 열수추출물의 수율은 4.45% 이었고, 70% 에탄올 추출물의 수율은 3.07%, 70% 에탄올 추출물의 수율은 2.21%이었고, 100% 에탄올 추출물의 수율은 0.3%로 열수추출물의 수율이 가장 높은 것으로 확인되었다.The yield of the hot water extract using dried Cissus was 4.45%, the yield of the 70% ethanol extract was 3.07%, the yield of the 70% ethanol extract was 2.21%, and the yield of the 100% ethanol extract was 0.3%. It was confirmed to be the highest.
용매에 따른 시서스 추출물의 미백 효능 확인Confirmation of whitening efficacy of Cissus extract according to solvent
2-1 : 멜라닌 생성 억제 효능2-1: Melanin production inhibition effect
흑색종(B16F1; Mouse melanoma cell line) 세포를 이용하여 실험을 진행하였으며, B16F1 세포는 FBS 및 1% 페니실린 스트렙토마이신을 포함한 DMEM 배지를 이용하여, 5% CO2, 37℃를 유지하면서 인큐베이터에서 배양하였다.The experiment was conducted using melanoma (B16F1; Mouse melanoma cell line) cells. B16F1 cells were cultured in an incubator using DMEM medium containing FBS and 1% penicillin streptomycin, maintaining 5% CO 2 and 37°C. did.
멜라닌 함량을 측정하기 위해, B16F1 세포를 8Х104 밀도로 60 mm 배양용기에 접종한 후, 시서스 열수 추출물(200 ㎍/㎖), 50% 에탄올 추출물(200 ㎍/㎖), 70% 에탄올 추출물(200 ㎍/㎖), 100% 에탄올 추출물(200 ㎍/㎖) 및 양성대조군인 코직산(kojic acid, 1 mM)을 각각 처리한 다음, α-멜라닌세포 자극 호르몬(α-MSH, 200 nM)을 처리하고, 72시간 동안 37℃에서 멜라닌 생성을 유도하였다. 72시간 후에 세포배양 배지를 150 ㎕씩 96 웰 플레이트로 로 옮겨서 세포 외 멜라닌 함량을 측정하였다. 세포는 회수한 후, 10% 다이메틸설폭시화물(DMSO)이 함유된 1M 수산화나트륨(NaOH)을 넣고 80℃에서 1시간 동안 넣어 멜라닌을 녹인 후 흡광도 405 nm에서 세포 내 멜라닌의 함량을 측정하였다.To measure melanin content, B16F1 cells were inoculated into a 60 mm culture dish at a density of 8Х10 4 and then treated with Cissus hydrothermal extract (200 ㎍/㎖), 50% ethanol extract (200 ㎍/㎖), and 70% ethanol extract ( 200 ㎍/㎖), 100% ethanol extract (200 ㎍/㎖), and kojic acid (1 mM) as a positive control, respectively, followed by treatment with α-melanocyte stimulating hormone (α-MSH, 200 nM). And melanin production was induced at 37°C for 72 hours. After 72 hours, 150 ㎕ of cell culture medium was transferred to a 96-well plate and the extracellular melanin content was measured. After the cells were recovered, 1M sodium hydroxide (NaOH) containing 10% dimethyl sulfoxide (DMSO) was added and stored at 80°C for 1 hour to dissolve melanin, and then the content of melanin in the cells was measured at an absorbance of 405 nm. .
그 결과, α-MSH를 처리하여 멜라닌 합성을 유도하였을 때 세포외 멜라닌 방출양은 179%로 증가하였다 . 반면, 시서스 열수 추출물, 50% 에탄올 추출물, 70% 에탄올 추출물 및 100% 에탄올 추출물을 처리하였을 때 각각 세포외 멜라닌 방출양은 135%, 136%, 149%, 193%로 감소하였으며, 양성대조군인 코직산을 처리하였을 때 세포 외 멜라닌 방출양은 128%로 나타내었다 (도 2A). As a result, when melanin synthesis was induced by treatment with α-MSH, the amount of extracellular melanin released increased to 179%. On the other hand, when treated with Cissus hot water extract, 50% ethanol extract, 70% ethanol extract, and 100% ethanol extract, the amount of extracellular melanin released decreased by 135%, 136%, 149%, and 193%, respectively, and kojic acid, a positive control, When treated, the amount of extracellular melanin released was 128% (Figure 2A).
또한, 세포 내에 생성된 멜라닌 생성양을 측정한 결과, α-MSH를 처리하였을 때 멜라닌 생성량이 182% 로 증가하였다. 반면, 시서스 열수 추출물, 50% 에탄올 추출물, 70% 에탄올 추출물 및 100% 에탄올 추출물을 처리하였을 때는 세포 내 멜라닌 생성양이 각각 115%, 122%, 138%, 111%로 억제되었으며, 양성대조군인 코직산을 처리하였을 때 세포 낸 멜라닌 생성량은 129%로 확인되었다 (도 2B).Additionally, as a result of measuring the amount of melanin produced within the cells, the amount of melanin produced increased by 182% when treated with α-MSH. On the other hand, when treated with Cissus hot water extract, 50% ethanol extract, 70% ethanol extract, and 100% ethanol extract, the amount of melanin production in cells was suppressed by 115%, 122%, 138%, and 111%, respectively, and the positive control group When treated with kojic acid, the amount of melanin produced by cells was confirmed to be 129% (Figure 2B).
2-2 : 세포 독성 확인2-2: Confirmation of cytotoxicity
시서스 추출물의 세포독성평가는 MTT 어세이 방법으로 확인하였다. Cytotoxicity evaluation of Cissus extract was confirmed by MTT assay method.
B16F1 세포를 1Х104 밀도로 24 웰 플레이트에 접종한 후 다음날, 시서스 열수 추출물(200 ㎍/㎖), 50% 에탄올 추출물(200 ㎍/㎖), 70% 에탄올 추출물(200 ㎍/㎖), 100% 에탄올 추출물(200 ㎍/㎖) 및 양성대조군인 코직산(kojic acid, 1 mM)을 각각 처리한 다음, α-멜라닌세포 자극 호르몬(α-MSH, 200 nM)을 처리하고, 72시간 동안 37℃에서 배양하였다. The next day after inoculating B16F1 cells in a 24-well plate at a density of 1Х10 4 , Cissus hydrothermal extract (200 ㎍/㎖), 50% ethanol extract (200 ㎍/㎖), 70% ethanol extract (200 ㎍/㎖), 100 % ethanol extract (200 ㎍/㎖) and kojic acid (1 mM) as a positive control, respectively, followed by treatment with α-melanocyte stimulating hormone (α-MSH, 200 nM), and incubated at 37°C for 72 hours. It was cultured in .
72시간 후에, MTT 시약이 포함된 배지로 교체한 후 37℃에서 1시간 동안 더 배양하였다. MTT 시약이 함유된 배지를 제거하고, 다이메틸설폭시화물(DMSO) 400 ㎕를 넣어 보라색으로 생성된 포르마잔(formazan)을 용해시켰다. 용해물질을 96 웰 플레이트로 100 ㎕씩 옮긴 후, 540 nm에서 흡광도를 측정하였다. α-MSH를 처리하지 않은 대조군의 생존율을 100%로 하여 세포 생존율을 계산하였다.After 72 hours, the medium was replaced with MTT reagent and cultured at 37°C for another hour. The medium containing the MTT reagent was removed, and 400 ㎕ of dimethyl sulfoxide (DMSO) was added to dissolve the purple-colored formazan. After transferring 100 μl of the dissolved material to a 96 well plate, the absorbance was measured at 540 nm. Cell survival rate was calculated by taking the survival rate of the control group that was not treated with α-MSH as 100%.
그 결과, 시서스 열수 추출물 및 50% 에탄올 추출물은 200 ㎍/㎖ 농도에서 세포 독성이 없는 것으로 확인되었다. 반면, 70% 에탄올 추출물, 100% 에탄올 추출물을 같은 농도로 처리하였을 때 세포의 생존율이 각각 73%, 55%로 세포 독성을 보이는 것을 확인하였다 (도 2C). 즉, 상기 실시예 2-1에서 70% 에탄올 추출물 및 100% 에탄올 추출물의 멜라닌 생성 억제 효능을 세포 독성으로 인해 기인된 것으로, 실제로는 멜라닌 생성 억게 효능 미미한 것을 의미한다.As a result, it was confirmed that Cissus hot water extract and 50% ethanol extract were not cytotoxic at a concentration of 200 μg/ml. On the other hand, when treated with 70% ethanol extract and 100% ethanol extract at the same concentration, cell survival rates were 73% and 55%, respectively, showing cytotoxicity (Figure 2C). That is, in Example 2-1, the melanin production-suppressing effect of the 70% ethanol extract and the 100% ethanol extract was attributed to cytotoxicity, which means that in reality, the melanin production-suppressing effect was minimal.
본 발명에서는 시서스 열수 추출물 및 50% 에탄올 추출물의 멜라닌 생성억제 효능이 우수한 것을 확인하였으며, 특히, 시서스 열수 추출물이 추출 수율 및 멜라닌 생성 억제 효능이 가장 우수한 것으로 나타났다.In the present invention, it was confirmed that Cissus hot water extract and 50% ethanol extract were excellent in melanin production inhibition efficacy. In particular, Cissus hot water extract was found to have the best extraction yield and melanin production inhibition efficacy.
시서스 열수 추출물의 멜라닌 생성 억제 효능 확인Confirmation of the efficacy of Cissus thermal water extract in inhibiting melanin production
본 발명에서는 세포 독성 없이 멜라닌 생성 억제 효능이 가장 우수한 시서스 열수 추출물의 농도에 따른 멜라닌 생성 억제 효능을 확인하였다.In the present invention, the melanin production inhibitory effect according to the concentration of Cissus thermal water extract, which has the best melanin production inhibitory effect without cytotoxicity, was confirmed.
상기 실시예 2-1과 동일한 방법으로 세포 외 멜라닌 방출량 및 세포 내 멜라닌 생성량을 측정하였으며, 시서스 열수 추출물은 각각 50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖ 농도로 처리하였다. Extracellular melanin release and intracellular melanin production were measured in the same manner as in Example 2-1, and Cissus thermal water extract was treated at concentrations of 50 μg/ml, 100 μg/ml, and 200 μg/ml, respectively.
세포 외 멜라닌 방출량의 경우, α-MSH로 멜라닌 합성을 유도하였을 때 무처리 군에 비해 멜라닌 양이 173%로 증가하였으며, 시서스 열수 추출물을 농도별로 처리하였을 때 각각 166%, 156%, 133%로 농도의존적으로 세포외 멜라닌 방출량이 감소하였으며, 양성 대조군인 코직산을 처리하였을 때 세포외 멜라닌 방출량은 103%로 감소하였다 (도 3A).In the case of extracellular melanin release, when melanin synthesis was induced with α-MSH, the amount of melanin increased to 173% compared to the untreated group, and when treated with Cissus hot water extract at different concentrations, it increased by 166%, 156%, and 133%, respectively. The amount of extracellular melanin released decreased in a concentration-dependent manner, and when treated with kojic acid, a positive control, the amount of extracellular melanin released decreased to 103% (Figure 3A).
세포 내 멜라닌 생성량의 경우, α-MSH를 처리하였을 때 멜라닌 생성양이 193%로 증가하였다. 시서스 열수추출물을 농도별로 처리하였을 때는 각각 179%, 170%, 151%로 농도의존적으로 멜라닌 생성양이 감소하였으며, 양성 대조군인 코직산을 처리하였을 때는 세포 내 멜라닌 생성양은 138%로 감소하였다 (도 3B). In the case of intracellular melanin production, the amount of melanin production increased to 193% when treated with α-MSH. When Cissus hot water extract was treated at different concentrations, the amount of melanin production decreased in a concentration-dependent manner by 179%, 170%, and 151%, respectively, and when treated with kojic acid, a positive control, the amount of intracellular melanin production decreased to 138% (Figure 3B).
즉, 본 발명의 시서스 열수추출물이 효과적으로 멜라닌 생성을 억제하는 것을 확인하였으며, 이는 양성대조군인 코직산 보다 현저하게 우수한 것으로 나타났다.In other words, it was confirmed that the Cissus hot water extract of the present invention effectively inhibits melanin production, and it was found to be significantly superior to kojic acid, a positive control.
시서스 열수 추출물의 티로시아나제 활성 억제 효능 확인Confirmation of inhibitory effect on tyrosyanase activity of Cissus thermal water extract
본 발명에서는 시서스 열수 추출물의 멜라닌 생성 억제 효과가 멜라닌 생성 과정의 주요 효소인 티로시나아제(tyrosinase) 활성 억제에 의한 것인지 확인하고자 하였다.In the present invention, we sought to determine whether the melanin production inhibition effect of Cissus thermal water extract was due to inhibition of tyrosinase activity, a key enzyme in the melanin production process.
먼저, B16F1 세포를 8 Х 104 밀도로 60 mm 배양용기에 접종한 다음, 다양한 농도의 시서스 열수 추출물(50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖)과 양성대조군인 코직산(kojic acid, 1 mM)을 각각 처리한 다음, α-멜라닌세포 자극 호르몬(α-MSH, 200 nM)을 처리하고, 72시간 동안 37℃에서 배양하였다. First, B16F1 cells were inoculated into a 60 mm culture vessel at a density of 8 Х 10 4 and then various concentrations of Cissus hydrothermal extract (50 ㎍/㎖, 100 ㎍/㎖ and 200 ㎍/㎖) and kojic acid (kojic acid) as a positive control were added. acid, 1 mM), and then treated with α-melanocyte stimulating hormone (α-MSH, 200 nM) and cultured at 37°C for 72 hours.
72시간 배양 후 PBS(phosphate buffered saline)로 세척하여 세포를 수득한 다음, 용해 버퍼(lysis buffer; PRO-PREP, iNtRON, 한국)를 이용하여 단백질을 추출하였다. 추출한 단백질을 정량한 다음, 96웰 플레이트에 동일한 양의 단백질을 넣은 후, L-도파(L-dopa, 2 mg/㎖)를 첨가하고 37℃에서 1시간 동안 반응시킨 후, 450nm에서 흡광도를 측정하였다. 티로시나아제의 활성도는 α-MSH를 처리하지 않은 대조군의 흡광도에 대한 백분율로 계산하였다.After 72 hours of incubation, cells were obtained by washing with PBS (phosphate buffered saline), and then proteins were extracted using lysis buffer (PRO-PREP, iNtRON, Korea). After quantifying the extracted protein, put the same amount of protein in a 96-well plate, add L-dopa (2 mg/ml), react at 37°C for 1 hour, and measure the absorbance at 450 nm. did. Tyrosinase activity was calculated as a percentage of the absorbance of the control group that was not treated with α-MSH.
그 결과, 시서스 열수 추출물에 의하여 농도 의존적으로 티로시나아제 활성 억제이 억제되는 것을 확인하였다 (도 4). α-MSH를 처리하였을 때는 무처리군에 비하여 티로시나아제 활성이 359% 증가한 반면, 시서스 열수 추출물을 50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖로 처리하였을 때 티로시나아제 활성이 각각 337%, 315%, 203%로, 시서스 열수 추출물 농도의존적으로 감소하였다. 특히, 시서스 열수추출물을 200 ㎍/㎖ 농도를 처리하였을 때 양성대조군인 코직산 보다 우수한 티로시나아제 활성 억제 효과를 보이는 것을 확인하였다.As a result, it was confirmed that inhibition of tyrosinase activity was suppressed by Cissus hot water extract in a concentration-dependent manner (Figure 4). When treated with α-MSH, tyrosinase activity increased by 359% compared to the untreated group, while when treated with Cissus thermal water extract at 50 ㎍/㎖, 100 ㎍/㎖, and 200 ㎍/㎖, tyrosinase activity increased by 359% compared to the untreated group. It decreased by 337%, 315%, and 203%, respectively, depending on the concentration of Cissus hot water extract. In particular, it was confirmed that when Cissus hot water extract was treated at a concentration of 200 ㎍/㎖, it showed a superior tyrosinase activity inhibition effect than the positive control, kojic acid.
시서스 열수 추출물의 미백 관련 단백질 발현 조절 효능 확인Confirmation of the efficacy of Cissus thermal water extract in regulating whitening-related protein expression
본 발명에서는 시서스 열수 추출물이 미백 관련 단백질 발현을 조절하는지 확인하기 위해, 멜라닌 생성 과정의 주요 효소인 티로시나아제 및 MITF(Microphthalmia-associated transcription factor)의 발현을 관찰하였다. MITF는 멜라닌합성 과정에 서 중요한 전사 조절 인자로 티로시나아제(tyrosinase), TRP-1 및 TRP-2의 전사를 촉진시키는 것으로 알려져있다.In the present invention, in order to determine whether Cissus thermal water extract regulates the expression of whitening-related proteins, the expression of tyrosinase and MITF (Microphthalmia-associated transcription factor), which are key enzymes in the melanin production process, was observed. MITF is an important transcriptional regulator in the melanin synthesis process and is known to promote the transcription of tyrosinase, TRP-1, and TRP-2.
먼저, 티로시나아제 단백질 발현 변화를 확인하기 위해, B16F1 세포를 8Х104 밀도로 60 mm 배양용기에 접종한 다음, 시서스 열수 추출물(50 ㎍/㎖, 100 ㎍/㎖, 200 ㎍/㎖) 및 양성대조군인 코직산(kojic acid, 1 mM)을 각각 처리한 다음, α-멜라닌세포 자극 호르몬(α-MSH, 200 nM)을 처리하고, 72시간 동안 37℃에서 배양하였다. MITF 단백질 발현 변화는 상기와 동일하게 각 시료를 처리한 다음, 4시간 동안 37℃에서 배양하였다. First, to confirm changes in tyrosinase protein expression, B16F1 cells were inoculated into a 60 mm culture dish at a density of 8Х10 4 and then treated with Cissus hot water extract (50 ㎍/㎖, 100 ㎍/㎖, 200 ㎍/㎖) and Each was treated with kojic acid (1 mM), a positive control, and then treated with α-melanocyte stimulating hormone (α-MSH, 200 nM), and cultured at 37°C for 72 hours. For changes in MITF protein expression, each sample was treated in the same manner as above and then incubated at 37°C for 4 hours.
시료 처리가 완료된 세포는 PBS로 세척한 후 용해버퍼를 이용하여 단백질을 추출하였다. 추출한 단백질은 브레드포드 어세이(Bradford assay) 방법으로 정량 하였으며, 정량한 단백질은 10 % SDS-PAGE(SDS polyacrylamide gel electrophoresis)로 분리한 후 PVDF(polyvinylidene difluoride) 멤브레인으로 트랜스퍼하였다. 멤브레인은 TBS-T(Tris-buffered saline-Tween 20 solutions)으로 녹인 5% 스킴 밀크로 1시간 동안 블로킹하였으며, TBS-T로 세척 후 티로시나아제, MITF 및 β-엑틴 1차 항체로 4℃에서 하룻밤 동안 반응시켰다. 다음날, 멤브레인을 TBS-T로 세척한 후 2차 항체(anti-mouse 및 anti-rabbit IgG)로 상온에서 1시간 반응시켰다. 단백질 밴드는 HRP 기질 및 ImageQuant LAS 500 (GE Healthcare Life Science, 미국)을 통해 확인하였다.After sample processing was completed, cells were washed with PBS and proteins were extracted using lysis buffer. The extracted proteins were quantified using the Bradford assay method, and the quantified proteins were separated using 10% SDS-PAGE (SDS polyacrylamide gel electrophoresis) and then transferred to a PVDF (polyvinylidene difluoride) membrane. The membrane was blocked with 5% skim milk dissolved in TBS-T (Tris-buffered saline-Tween 20 solutions) for 1 hour, washed with TBS-T, and then incubated with tyrosinase, MITF, and β-actin primary antibodies at 4°C. The reaction was allowed to occur overnight. The next day, the membrane was washed with TBS-T and reacted with secondary antibodies (anti-mouse and anti-rabbit IgG) at room temperature for 1 hour. Protein bands were confirmed using HRP substrate and ImageQuant LAS 500 (GE Healthcare Life Science, USA).
그 결과, α-MSH만 처리하였을 때 무처리군에 비해 티로시나아제 및 MITF 단백질이 각각 500% 및 350% 정도 증가한 반면, 시서스 열수 추출물을 50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖로 처리하였을 때, 티로시나아제 및 MITF 단백질이 시서스 열수 추출물 농도 의존적으로 감소되는 것을 확인하였다 (도 5). 따라서, 따라서, 시서스 열수추출물이 티로시나아제 및 MITF 단백질 발현 억제를 통하여 멜라닌 생성을 저해함을 확인하였다. As a result, when only α-MSH was treated, tyrosinase and MITF proteins increased by about 500% and 350%, respectively, compared to the untreated group, while Cissus hot water extract was treated at 50 ㎍/㎖, 100 ㎍/㎖, and 200 ㎍/㎖. When treated with ㎖, it was confirmed that tyrosinase and MITF proteins were reduced in a concentration-dependent manner of Cissus hot water extract (FIG. 5). Therefore, it was confirmed that Cissus hot water extract inhibits melanin production through inhibition of tyrosinase and MITF protein expression.
시서스 열수 추출물 분획물 제조Preparation of Cissus hydrothermal extract fractions
시서스 열수 추출물 분획물은 도 6에 나타낸 모식도와 같은 방법으로 헥산 분획물, 클로로포름 분획물, 에틸아세테이트 분획물, 부탄올 분획물, 및 물 분획물을 수득하였다. Cissus hydrothermal extract fractions were obtained as hexane fraction, chloroform fraction, ethyl acetate fraction, butanol fraction, and water fraction in the same manner as the schematic diagram shown in FIG. 6.
구체적으로, 시서스 열수추출물 1.3 g에 각각의 분획용매를 130 ㎖씩 혼합한 다음, 혼합물을 강하게 섞은 후 정치시켜 층별 분리를 3번씩 하였다. 용매별 분획물은 감압농축한 후 동결건조하여 시료로 사용하였다. Specifically, 1.3 g of Cissus hot water extract was mixed with 130 ml of each fractionation solvent, then the mixture was vigorously mixed and allowed to stand to separate layers three times. Fractions for each solvent were concentrated under reduced pressure, freeze-dried, and used as samples.
각 분획물의 수율은 헥산 분획물(44.43%), 클로로포름 분획물층(14.86%), 에틸아세테이트 분획물(0.22%), 부탄올 분획물(1.39%), 물 분획물(26.5%)으로 헥산 분획물 > 물 분획물 > 클로로포름 분획물 > 부탄올 분획물 > 에틸아세테이트 분획물으로 수율이 높은 것으로 나타났다.The yield of each fraction was hexane fraction (44.43%), chloroform fraction layer (14.86%), ethyl acetate fraction (0.22%), butanol fraction (1.39%), and water fraction (26.5%): hexane fraction > water fraction > chloroform fraction. > Butanol fraction > ethyl acetate fraction showed high yield.
시서스 열수 추출물의 분획물에 대한 미백 효능 확인Confirmation of whitening efficacy of fractions of Cissus thermal water extract
7-1 : 멜라닌 생성 억제 효능 확인7-1: Confirmation of melanin production inhibition effect
상기 실시예 6에서 제조한 각 분획물 200 ㎍/㎖, 코직산(kojic acid, 1 mM)을 각각 처리한 다음, α-멜라닌세포 자극 호르몬(α-MSH, 200 nM)을 처리하고, 72시간 동안 37℃에서 배양하였다. 그 다음, 상기 실시예 2-1과 동일한 방법으로 세포외 멜라닌 방출량 및 세포내 멜라닌 생성량을 측정하였다.Each fraction prepared in Example 6 was treated with 200 μg/ml of kojic acid (1 mM), then treated with α-melanocyte stimulating hormone (α-MSH, 200 nM), and incubated for 37 hours for 72 hours. Cultured at ℃. Next, the amount of extracellular melanin released and the amount of intracellular melanin produced were measured in the same manner as in Example 2-1.
그 결과, 도 7A 및 도 7B에 나타난 바와 같이, a-MSH만 처리한 군은 멜라닌 함량이 대조군에 비하여 뚜렷하게 증가한 반면, 부탄올 분획물(BF)을 제외한 헥산 분획물(HF), 클로로포름 분획물(CF), 에틸아세테이트 분획물(EF), 및 물 분획물(WF)은 세포외 멜라닌과 세포내 멜라닌 생성양이 억제되는 것으로 나타났다.As a result, as shown in Figures 7A and 7B, the melanin content of the group treated only with a-MSH was significantly increased compared to the control group, while the hexane fraction (HF), chloroform fraction (CF), and butanol fraction (BF) were excluded. The ethyl acetate fraction (EF) and water fraction (WF) were shown to inhibit the amount of extracellular melanin and intracellular melanin production.
a-MSH로 자극하였을 때의 세포외 멜라닌 방출량은 무처리 대조군을 100%로 하였을 때 176.8±5.6%이었고, 헥산 분획물은 161.5±2.2%, 클로로포름 분획물은 162.1±3.6%, 에틸아세테이트 분획물은 137.6±5.0%, 부탄올 분획물은 174.3±0.8%, 물 분획물은 167.7±2.6%를 나타내었다. The amount of extracellular melanin released when stimulated with a-MSH was 176.8±5.6% when the untreated control was set as 100%, the hexane fraction was 161.5±2.2%, the chloroform fraction was 162.1±3.6%, and the ethyl acetate fraction was 137.6±5.6%. 5.0%, butanol fraction was 174.3 ± 0.8%, and water fraction was 167.7 ± 2.6%.
또한, a-MSH 처리군의 세포내 멜라닌 생성량은 대조군을 100%로 하였을 때 207.1±1.6%이었고, 헥산 분획물은 186.3±0.8%, 클로로포름 분획물은 182.8±2.5%, 에틸아세테이트 분획물은 113.01±2.5%, 부탄올 분획물은 176.3±0.0%, 물 분획물은 209.4±5.0%, 코직산을 처리하였을 때는 159.1±2.5%를 나타내었다. In addition, the amount of intracellular melanin production in the a-MSH treated group was 207.1 ± 1.6% when the control group was set at 100%, the hexane fraction was 186.3 ± 0.8%, the chloroform fraction was 182.8 ± 2.5%, and the ethyl acetate fraction was 113.01 ± 2.5%. , the butanol fraction was 176.3 ± 0.0%, the water fraction was 209.4 ± 5.0%, and when treated with kojic acid, it was 159.1 ± 2.5%.
특히, 에틸아세테이트 분획물을 처리하였을 때 멜라닌 생성량이 현저히 억제되었으며 양성대조군인 코직산보다 세포내 멜라닌 생성 억제 효과가 우수한 것을 확인하였다.In particular, when the ethyl acetate fraction was treated, the amount of melanin production was significantly suppressed, and it was confirmed that the effect of suppressing intracellular melanin production was superior to that of kojic acid, which was a positive control.
7-2 : 티로시나아제 활성 측정7-2: Measurement of tyrosinase activity
상기 실시예 6에서 제조한 각 분획물을 실시예 4와 동일한 방법으로 처리하여 티로시나아제 활성을 특정하였다. Each fraction prepared in Example 6 was treated in the same manner as Example 4 to determine tyrosinase activity.
그 결과, 도 7C에 나타난 바와 같이, a-MSH 처리에 의해 증가된 티로시나아제 활성은 시서스 열수 추출물의 각 분획물에 의해 감소하였으며, 특히, 에틸아세테이트 분획물이 티로시나아제 활성을 가장 우수하게 억제하는 것을 확인하였다. As a result, as shown in Figure 7C, the tyrosinase activity increased by a-MSH treatment was decreased by each fraction of Cissus hot water extract, and in particular, the ethyl acetate fraction inhibited tyrosinase activity the best. It was confirmed that
7-3 : 세포 독성 확인7-3: Confirmation of cytotoxicity
시서스 열수 추출물의 각 분획물에 따른 세포독성을 확인하기 위하여 상기 실시예 2-2와 동일한 방법으로 세포 생존율을 측정하였다.In order to confirm the cytotoxicity of each fraction of Cissus hot water extract, cell viability was measured in the same manner as in Example 2-2.
도 7D에 나타난 바와 같이, 세포의 생존율은 부탄올 분획물 (94.1±0.46%) < 클로로포름 분획물 (94.1±0.9%) < 헥산 분획물 (95.2±2.8%) < 물 분획물 (98.5±1.8%) < 에틸아세테이트 분획물 (108.2±0.6%) 순으로 높은 것으로 나타났으며, 분획물 모두 세포생존율이 94% 이상으로 세포 독성은 관찰되지 않았다.As shown in Figure 7D, the cell survival rate was as follows: butanol fraction (94.1 ± 0.46%) < chloroform fraction (94.1 ± 0.9%) < hexane fraction (95.2 ± 2.8%) < water fraction (98.5 ± 1.8%) < ethyl acetate fraction. (108.2±0.6%), and the cell viability of all fractions was over 94% and no cytotoxicity was observed.
시서스 열수 추출물의 에틸아세테이트 분획물의 미백효능 확인Confirmation of whitening effect of ethyl acetate fraction of Cissus thermal water extract
본 발명에서는 시서스 열수 추출물의 분획물 중 멜라닌 생성 억제 효능이 가장 우수한 에틸아세테이트 분획물(EF)의 농도에 따른 미백 효능을 확인하고자 하였다. In the present invention, we sought to confirm the whitening effect according to the concentration of the ethyl acetate fraction (EF), which has the best melanin production inhibition effect among the fractions of Cissus thermal water extract.
8-1 : 멜라닌 생성 억제 효능8-1: Melanin production inhibition effect
상기 실시예 2-1과 동일한 방법으로 세포 외 멜라닌 방출량 및 세포 내 멜라닌 생성량을 측정하였으며, 시서스 열수 추출물의 에틸아세테이트 분획물은 각각 50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖ 농도로 처리하였다. The amount of extracellular melanin released and the amount of intracellular melanin produced were measured in the same manner as in Example 2-1, and the ethyl acetate fraction of Cissus thermal water extract was treated at concentrations of 50 μg/ml, 100 μg/ml, and 200 μg/ml, respectively. did.
세포 외 멜라닌 방출량의 경우, α-MSH로 멜라닌 합성을 유도하였을 때 무처리 군에 비해 멜라닌 양이 231.8%로 증가한 반면, 시서스 열수 추출물의 에틸아세테이트 분획물을 농도별로 처리하였을 때 각각 216.7%, 173.0%, 156.5%로 농도의존적으로 세포외 멜라닌 방출량이 감소하였다 (도 8A).In the case of extracellular melanin release, when melanin synthesis was induced with α-MSH, the amount of melanin increased to 231.8% compared to the untreated group, whereas when the ethyl acetate fraction of Cissus thermal water extract was treated at different concentrations, it increased to 216.7% and 173.0%, respectively. %, the amount of extracellular melanin released decreased in a concentration-dependent manner by 156.5% (Figure 8A).
세포 내 멜라닌 생성량의 경우, α-MSH로 멜라닌 합성을 유도하였을 때 무처리 군에 비해 멜라닌 양이 178.2%로 증가한 반면, 시서스 열수 추출물의 에틸아세테이트 분획물을 농도별로 처리하였을 때 각각 152.0%, 141.1%, 133.1%로 농도의존적으로 세포 내 멜라닌 생성량이 감소하였다 (도 8B).In the case of intracellular melanin production, when melanin synthesis was induced with α-MSH, the amount of melanin increased to 178.2% compared to the untreated group, whereas when treated with the ethyl acetate fraction of Cissus thermal water extract at different concentrations, it increased to 152.0% and 141.1%, respectively. %, the amount of melanin produced in cells decreased in a concentration-dependent manner by 133.1% (Figure 8B).
8-2 : 티로시나아제 활성 억제 효능8-2: Tyrosinase activity inhibition effect
상기 실시예 4와 동일한 방법으로 티로시나아제 활성을 측정하였으며, 시서스 열수 추출물의 에틸아세테이트 분획물은 각각 50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖ 농도로 처리하였다. Tyrosinase activity was measured in the same manner as in Example 4, and the ethyl acetate fraction of Cissus hot water extract was treated at concentrations of 50 μg/ml, 100 μg/ml, and 200 μg/ml, respectively.
그 결과, 도 8C에 나타난 바와 같이, α-MSH를 처리하였을 때 티로시나아제 활성이 441.5%로 증가한 반면, 시서스 열수 추출물의 에틸아세테이트 분획물을 농도별로 처리하였을 때 티로시나아제 활성은 각각 378.8 %, 303.3%, 162.7%로 억제되었다. As a result, as shown in Figure 8C, when treated with α-MSH, the tyrosinase activity increased to 441.5%, while when the ethyl acetate fraction of Cissus hot water extract was treated at different concentrations, the tyrosinase activity increased to 378.8%. , was suppressed by 303.3% and 162.7%.
특히 도 7의 결과와 마찬가지로, 양성대조군인 코직산에 비해 에틸아세테이트 분획물을 200 ㎍/㎖의 농도로 처리하였을 때 세포 내 멜라닌 생성 억제효능 및 티로시나아제 활성 억제 효과가 더 우수한 것으로 확인되었다. In particular, similar to the results in FIG. 7, it was confirmed that the efficacy of inhibiting intracellular melanin production and inhibiting tyrosinase activity was superior when the ethyl acetate fraction was treated at a concentration of 200 μg/ml compared to kojic acid, which was a positive control.
8-3 : 세포 독성 확인8-3: Confirmation of cytotoxicity
시서스 열수 추출물의 에틸아세테이트 분획물 농도 따른 세포독성을 확인하기 위하여 상기 실시예 2-2와 동일한 방법으로 세포 생존율을 측정하였다.In order to confirm cytotoxicity according to the concentration of the ethyl acetate fraction of Cissus hot water extract, cell viability was measured in the same manner as in Example 2-2.
그 결과, 도 8D에 나타난 바와 같이, 에틸아세테이트의 분획물을 농도별로 처리하였을 때 세포의 생존율은 모두 100% 이상으로 분획물에 의한 세포 독성은 관찰되지 않았으며, 오히려 세포의 생존율이 증가하는 것을 확인하였다.As a result, as shown in Figure 8D, when the fractions of ethyl acetate were treated at different concentrations, the cell survival rate was all over 100%, and no cytotoxicity was observed due to the fractions. Rather, it was confirmed that the cell survival rate increased. .
시서스 열수 추출물의 에틸아세테이트 분획물의 미백 관련 단백질 발현 조절 효능 확인Confirmation of the efficacy of ethyl acetate fraction of Cissus thermal water extract in regulating whitening-related protein expression
본 발명에서는 시서스 열수 추출물의 에틸아세테이드 분획물이 멜라닌 생성 과정의 주요 효소인 티로시나아제 및 MITF의 발현을 조절하는지 확인하였다. In the present invention, it was confirmed whether the ethyl acetate fraction of Cissus thermal water extract regulates the expression of tyrosinase and MITF, which are key enzymes in the melanin production process.
상기 실시예 5와 동일한 방법으로 실험을 수행하였으며, 시서스 열수 추출물의 에틸아세테이트 분획물은 각각 50 ㎍/㎖, 100 ㎍/㎖ 및 200 ㎍/㎖ 농도로 처리하였다. The experiment was performed in the same manner as in Example 5, and the ethyl acetate fraction of Cissus hot water extract was treated at concentrations of 50 μg/ml, 100 μg/ml, and 200 μg/ml, respectively.
그 결과, 도 9에 나타난 바와 같이, 시서스 열수 추출물의 에틸아세테이트 분획물 농도 의존적으로 티로시나아제 및 MITF 발현이 억제되는 것을 확인하였으며, 200 ㎍/㎖ 농도의 에틸아세테이트 분획물의 경우, 양성대조군인 코직산 처리군에 비해 티로시나아제 발현 억제 효능이 더 우수한 것을 확인하였다.As a result, as shown in Figure 9, it was confirmed that tyrosinase and MITF expression was suppressed in a concentration-dependent manner in the ethyl acetate fraction of the Cissus hot water extract. In the case of the ethyl acetate fraction at a concentration of 200 μg/ml, kojic acid, a positive control, It was confirmed that the efficacy of inhibiting tyrosinase expression was superior compared to the treatment group.
Claims (12)
A cosmetic composition for skin whitening comprising Cissus quadrangularis thermal water extract or its ethyl acetate fraction as an active ingredient.
The cosmetic composition for skin whitening according to claim 1, wherein the Cissus is a Cissus stem or Cissus leaf.
The cosmetic composition for skin whitening according to claim 1, wherein the Cissus hydrothermal extract or its ethyl acetate fraction is contained in a concentration of 10 to 500 μg/ml.
The cosmetic composition for skin whitening according to claim 1, wherein the Cissus hot water extract is extracted by adding 5 to 15 liters of water per 100 parts by weight of Cissus and then applying heat for 1 to 3 hours.
(a) 시서스 열수 추출물에서 헥산 용매를 첨가한 다음, 수상(aqueous phase)을 수득하는 단계;
(b) 상기 수상에 클로로포름 용매를 첨가한 다음, 수상을 수득하는단계; 및
(c) 상기 수상에 에틸아세테이트 용매를 첨가한 다음, 에틸아세테이트 분획물을 수득하는 단계;를 포함하는 방법으로 제조되는 것을 특징으로 하는, 피부 미백용 화장료 조성물.
The method of claim 1, wherein the ethyl acetate fraction is
(a) adding hexane solvent to the Cissus hydrothermal extract and then obtaining an aqueous phase;
(b) adding chloroform solvent to the aqueous phase and then obtaining the aqueous phase; and
(c) adding an ethyl acetate solvent to the aqueous phase and then obtaining an ethyl acetate fraction. A cosmetic composition for skin whitening, characterized in that it is prepared by a method comprising:
The cosmetic composition for skin whitening according to claim 1, wherein the Cissus hydrothermal extract or its ethyl acetate fraction inhibits melanin production or tyrosinase activity.
The method of claim 1, wherein the Cissus hot water extract or its ethyl acetate fraction inhibits melanin production or tyrosinase activity by inhibiting MITF (Microphthalmia-associated transcription factor) production. Cosmetic composition for skin whitening.
A health functional food composition for skin whitening comprising Cissus thermal water extract or its ethyl acetate fraction as an active ingredient.
A pharmaceutical composition for preventing or treating skin pigmentation disease, comprising Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient.
The pharmaceutical composition for preventing or treating skin pigmentation disease according to claim 9, wherein the skin pigmentation disease is melasma, freckles, or melanoma.
A quasi-drug composition for preventing or improving skin pigmentation disease, comprising Cissus thermal water extract or an ethyl acetate fraction thereof as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220079107A KR102691782B1 (en) | 2022-06-28 | 2022-06-28 | Composition for Skin Whitening Comprising Extract or Fraction of Cissus Quadrangularis as an Active Ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220079107A KR102691782B1 (en) | 2022-06-28 | 2022-06-28 | Composition for Skin Whitening Comprising Extract or Fraction of Cissus Quadrangularis as an Active Ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20240002018A true KR20240002018A (en) | 2024-01-04 |
KR102691782B1 KR102691782B1 (en) | 2024-08-06 |
Family
ID=89542445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220079107A KR102691782B1 (en) | 2022-06-28 | 2022-06-28 | Composition for Skin Whitening Comprising Extract or Fraction of Cissus Quadrangularis as an Active Ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102691782B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210020438A (en) * | 2019-08-14 | 2021-02-24 | 전은희 | Cosmetic composition for improving blood circulation, including cissus and spring onion fermented extract |
KR20210083615A (en) * | 2019-12-27 | 2021-07-07 | 주식회사 디볼베르코스메틱 | Jaw-line correction cosmetic mask pack and method of preparing the same |
-
2022
- 2022-06-28 KR KR1020220079107A patent/KR102691782B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210020438A (en) * | 2019-08-14 | 2021-02-24 | 전은희 | Cosmetic composition for improving blood circulation, including cissus and spring onion fermented extract |
KR20210083615A (en) * | 2019-12-27 | 2021-07-07 | 주식회사 디볼베르코스메틱 | Jaw-line correction cosmetic mask pack and method of preparing the same |
Non-Patent Citations (4)
Title |
---|
Hae Jin Lee et al. Toxicology Reports, 2018, Vo. 5, pp. 608-614 * |
Ikuko Suzu et al. Natural Product Communications, 2013, Vol. 8, pp.629-630 * |
R.K. Lekshmi et al. Phytomedicine, 2015, Vol. 22, pp. 952-960 * |
Sidney J. Stohs et al. Phytotherapy Research, 2013, Vol. 27, pp. 1107-1114 * |
Also Published As
Publication number | Publication date |
---|---|
KR102691782B1 (en) | 2024-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101671852B1 (en) | Skin whitening composition containing extract or fraction of Euphorbia maculata or Euphorbia supina | |
KR20210108911A (en) | A composition for antioxidant or whitening compriging rosemary ionic liquid extract | |
KR102201305B1 (en) | A composition for skin whitening comprising Cimicifuga dahurica extract or a fraction thereof | |
KR102094949B1 (en) | Whitening composition containing extract, fractions or compound derived from Raphanus sativus L. var niger | |
KR102691782B1 (en) | Composition for Skin Whitening Comprising Extract or Fraction of Cissus Quadrangularis as an Active Ingredient | |
KR102502920B1 (en) | Methods of Ganoderma lucidum mycelia having enhanced whitening effect and use thereof | |
KR20180040756A (en) | Skin whitening composition comprising an extract of coixlachryma-jobi var. mayuen | |
KR20130023606A (en) | Composition for whitening of the skin comprising an extract of sophora japonica l., leguminosae | |
KR102349702B1 (en) | Skin whitening composition comprising crataegus pinnatifida extract or fractions thereof | |
KR102506620B1 (en) | A composition for promoting melanin synthesis comprising chrysoeriol | |
KR102283012B1 (en) | Whitening composition comprising an extract of Elaeagnus macrophylla or a fraction thereof as an active ingredient | |
KR102076933B1 (en) | Composition for skin whitening comprising carvone or its salt as active ingredients | |
KR102089209B1 (en) | Composition for skin whitening comprising guaiacol, phytol and cavacrol as active ingredients | |
WO2020256381A1 (en) | Skin whitening composition comprising octadecene or salt thereof as active ingredient | |
KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
KR20230099248A (en) | Composition for skin whitening comprising extract or fraction of Catalpa ovata as an active ingredient | |
KR20240078373A (en) | Composition for Skin Whitening Comprising Extract of Gracilaria vermiculophylla as an Active Ingredient | |
KR102631500B1 (en) | Composition for skin whitening comprising extract of hempseed meal as effective component | |
KR101526435B1 (en) | Compositions for skin-whitening comprising extract of Vitis amurensis ruprecht | |
KR102272742B1 (en) | Whitening composition containing Daphne odora | |
KR20200089527A (en) | Composition comprising extracts of Acorus gramineus and Dendropanax morbifera for anti-inflammation | |
KR102566131B1 (en) | Composition for skin whitening comprising mixed extract of ginseng and mulberry as effective component | |
KR102524917B1 (en) | Composition of skin whitening containing extract of lycopi herba and method of manufacturing the same | |
KR102482196B1 (en) | A composition for preventing or improving circadian rhythm disorders comprising Andrographis paniculata plant extracts or andrographolide | |
KR102034779B1 (en) | Cosmetic composition for skin whitening comprising ginsenoside Rh1 and Rg2 and extract of Hydrangea macrophylla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20220628 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240727 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240731 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20240801 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |